Garassino, M. C., Gadgeel, S., Novello, S., Halmos, B., Felip, E., Speranza, G., . . . Paz-Ares, L. (2025). Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]. JTO clinical and research reports, 6(10), 100892. https://doi.org/10.1016/j.jtocrr.2025.100892
Citácia podle Chicago (17th ed.)Garassino, Marina C., et al. "Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]." JTO Clinical and Research Reports 6, no. 10 (2025): 100892. https://doi.org/10.1016/j.jtocrr.2025.100892.
Citácia podľa MLA (8th ed.)Garassino, Marina C., et al. "Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]." JTO Clinical and Research Reports, vol. 6, no. 10, 2025, p. 100892, https://doi.org/10.1016/j.jtocrr.2025.100892.